Share on StockTwits

Analysts at Noble Financial dropped their price target on shares of PharmAthene (NYSE:PIP) to $6.00 in a research report issued to clients and investors on Monday. Noble Financial’s price objective would indicate a potential upside of 175.23% from the stock’s previous close.

Separately, analysts at Aegis raised their price target on shares of PharmAthene to $6.00 in a research note on Monday, August 11th.

PharmAthene (NYSE:PIP) traded down 3.21% during mid-day trading on Monday, hitting $2.11. The stock had a trading volume of 537,517 shares. PharmAthene has a 52 week low of $1.19 and a 52 week high of $2.42. The stock has a 50-day moving average of $1.45 and a 200-day moving average of $1.6. The company’s market cap is $119.1 million.

PharmAthene (NYSE:PIP) last posted its quarterly earnings results on Monday, August 4th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.05. Analysts expect that PharmAthene will post $-0.15 EPS for the current fiscal year.

PharmAthene, Inc is a biodefense company engaged in the development and commercialization of medical countermeasures against biological and chemical weapons.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.